Compare
Embecta Corp. vs Teleflex Inc vs West Pharmaceutical Services Inc vs Lemaitre Vascular Inc
| Latest fiscal year | Embecta Corp. EMBC | Teleflex Inc TFX | West Pharmaceutical Services Inc WST | Lemaitre Vascular Inc LMAT |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.08B | $1.99B | $3.07B | $249.60M |
| Revenue growth (YoY) | -3.8% | +17.2% | +6.3% | +13.5% |
| Gross margin | 62.6% | 56.2% | 35.9% | 71.5% |
| Operating margin | 22.4% | 5.9% | 19.0% | 27.2% |
| Net margin | 8.8% | -45.4% | 16.1% | 23.1% |
| Net income | $95.40M | -$905.64M | $493.70M | $57.73M |
| EPS (Diluted) | $1.62 | -$20.25 | $6.79 | $2.52 |
| Operating cash flow | $191.70M | $96.68M | $754.80M | $81.25M |
| Free cash flow | $182.40M | $1.45M | $468.90M | $74.47M |
| Cash & equivalents | $225.50M | $378.56M | $791.30M | $28.24M |
| Total assets | $1.09B | $6.95B | $4.27B | $615.69M |
| Total liabilities | n/a | $3.82B | $1.09B | $222.17M |
| Shareholders' equity | -$650.60M | $3.12B | $3.18B | $393.52M |
| Return on year-end equity | n/a | -29.0% | 15.5% | 14.7% |
| Shares outstanding | 58.50M | n/a | 72.00M | 22.77M |
Revenue, most recent five fiscal years
| Fiscal year | Embecta Corp. | Teleflex Inc | West Pharmaceutical Services Inc | Lemaitre Vascular Inc |
|---|---|---|---|---|
| Latest | $1.08B Ended 2025-09-30 | $1.99B Ended 2025-12-31 | $3.07B Ended 2025-12-31 | $249.60M Ended 2025-12-31 |
| 1 year earlier | $1.12B Ended 2024-09-30 | $1.70B Ended 2024-12-31 | $2.89B Ended 2024-12-31 | $219.86M Ended 2024-12-31 |
| 2 years earlier | $1.12B Ended 2023-09-30 | $1.71B Ended 2023-12-31 | $2.95B Ended 2023-12-31 | $193.48M Ended 2023-12-31 |
| 3 years earlier | $1.13B Ended 2022-09-30 | $2.79B Ended 2022-12-31 | $2.89B Ended 2022-12-31 | $161.65M Ended 2022-12-31 |
| 4 years earlier | $1.17B Ended 2021-09-30 | $2.81B Ended 2021-12-31 | $2.83B Ended 2021-12-31 | $154.42M Ended 2021-12-31 |